Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20165751 | 1.00 | CNR2 (0.31) | CNR2 | |
| SCHEMBL29874522 | 1.00 | CNR2 (0.31) | CNR2 | |
| SCHEMBL20180234 | 0.90 | CNR2 (0.31) | CNR2 | |
| SCHEMBL21451184 | 0.90 | CNR2 (0.33) | CNR2 | |
| SCHEMBL31355494 | 0.90 | CNR2 (0.33) | CNR2 | |
| SCHEMBL9955849 | 0.87 | ALOX5 (0.35) | — | |
| SCHEMBL22863196 | 0.84 | ACHE (0.42) | CNR2 | |
| SCHEMBL20180147 | 0.84 | ACHE (0.42) | CNR2 | |
| SCHEMBL20165703 | 0.84 | ACHE (0.42) | CNR2 | |
| SCHEMBL31342804 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110177798-B | Catalyst and process for preparing same | 博里利斯股份公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11352376-B2 | Catalysts | BOREALIS AG (AT) | 2022-06-07 | — | — | US | disclosed |
| US-11352376-B2 | Catalysts | BOREALIS AG (AT) | 2022-06-07 | — | — | US | disclosed |
| EP-3541823-B1 | CATALYSTS | BOREALIS AG (AT) | 2020-12-30 | — | — | EP | disclosed |
| EP-3541823-B1 | CATALYSTS | BOREALIS AG (AT) | 2020-12-30 | — | — | EP | disclosed |
| US-20190308995-A1 | CATALYSTS | BOREALIS AG (AT) | 2019-10-10 | — | — | US | disclosed |
| US-20190308995-A1 | CATALYSTS | BOREALIS AG (AT) | 2019-10-10 | — | — | US | disclosed |
| WO-2018091684-A1 | CATALYSTS | BOREALIS AG (AT) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352376-B2 | Catalysts | SIGMAR1, H1-2, SFN | CNR2 480/4885 |
| US-20190308995-A1 | CATALYSTS | SIGMAR1, H1-2, CBR1 | CNR2 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.